Company
MLA Diagnostics
A multi-parameter non-invasive melanoma risk assessment tool
- Status
- Operatingas of 2026-09-20
- Business model
- B2B
- Headquarters
- Maastricht, The Netherlands
- Customers
- clinicians
Claim, correct or request removal
Record updated 20 September 2026
About
MLA Diagnostics has developed an integrated multi-parameter risk assessment tool used to identify melanoma patients who based on molecular and clinical risk factors have a high chance of their melanoma spreading or recurring. The molecular assay is easily implemented into current laboratory workflows and enriches clinical and pathological information to support clinicians in clinical decision making and managing their patients treatment.
Funding snapshot
- Latest round
- Undisclosed2023-11-29
Funding rounds
- Round, 2023
- 2023-11-29
- Grant
- 2023-08-18
- Grant
- 2021-07-07
- Grant
- 2020-12-23
Products
- Other
- multi-parameter non-invasive melanoma risk assessment tool
Loading relationship preview